

Sheet 1 of 1

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.:

CV01382K

SERIAL NO.:

10/057,629

APPLICANT:

Harry R. Davis

FILING DATE:

01/25/2002

GROUP:

1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
ms	AL	WO 95/35277	12/28/95	PCT	C07D	205/08		
	AM							
	AN							
	AO							
	AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

ms	AQ	Thompson, G.R. et al., "Novel lipid-regulating drugs" <i>Expert Opinion on Investigational Drugs</i> 9(11):2619-2628 (2000), XP008011782 abstract; figure 8
ms	AR	Kosoglou, T. et al., "Coadministration of ezetimibe and fenofibrate leads to favorable effects on Apo CII and LDL subfractions" <i>Atherosclerosis</i> 2:89 (2001), XP1132089 abstract
	AS	
	AT	
	AU	
	AV	

EXAMINER

DATE CONSIDERED

10/16/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.